The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer

Overview

Journal Annu Rev Pathol

Publisher Annual Reviews

Specialty Pathology

Date 2016 Dec 14

PMID 27959632

Citations 323

Authors

Silvia Affo

Le-Xing Yu

Robert F Schwabe

Affiliations

Soon will be listed here.

Abstract

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than 700,000 deaths annually. Because of the wide landscape of genomic alterations and limited therapeutic success of targeting tumor cells, a recent focus has been on better understanding and possibly targeting the microenvironment in which liver tumors develop. A unique feature of liver cancer is its close association with liver fibrosis. More than 80% of hepatocellular carcinomas (HCCs) develop in fibrotic or cirrhotic livers, suggesting an important role of liver fibrosis in the premalignant environment (PME) of the liver. Cholangiocarcinoma (CCA), in contrast, is characterized by a strong desmoplasia that typically occurs in response to the tumor, suggesting a key role of cancer-associated fibroblasts (CAFs) and fibrosis in its tumor microenvironment (TME). Here, we discuss the functional contributions of myofibroblasts, CAFs, and fibrosis to the development of HCC and CCA in the hepatic PME and TME, focusing on myofibroblast- and extracellular matrix-associated growth factors, fibrosis-associated immunosuppressive pathways, as well as mechanosensitive signaling cascades that are activated by increased tissue stiffness. Better understanding of the role of myofibroblasts in HCC and CCA development and progression may provide the basis to target these cells for tumor prevention or therapy.

Citing Articles

Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC.

Kimura S, Iwano S, Akioka T, Kuchimaru T, Kawaguchi M, Fukushima T Int J Mol Sci. 2025; 26(5).

PMID: 40076928 PMC: 11900290. DOI: 10.3390/ijms26052308.

Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response.

Baquero C, Iniesta-Gonzalez M, Palao N, Fernandez-Infante C, Cueto-Remacha M, Mancebo J J Pathol. 2025; 265(4):502-517.

PMID: 39989399 PMC: 11880977. DOI: 10.1002/path.6403.

Integration of single-cell and spatial transcriptomics reveals fibroblast subtypes in hepatocellular carcinoma: spatial distribution, differentiation trajectories, and therapeutic potential.

Liu Y, Dong G, Yu J, Liang P J Transl Med. 2025; 23(1):198.

PMID: 39966876 PMC: 11837652. DOI: 10.1186/s12967-025-06192-0.

Deciphering the heterogeneity and plasticity of the tumor microenvironment in liver cancer provides insights for prognosis.

Sun Y, Shi G, Yang J, Zhou C, Peng C, Luo Y Front Pharmacol. 2025; 16:1495280.

PMID: 39950116 PMC: 11821625. DOI: 10.3389/fphar.2025.1495280.

An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy.

Chen Y, Pasquier D, Verstappen D, Woodruff H, Lambin P J Cancer Res Clin Oncol. 2025; 151(2):84.

PMID: 39948208 PMC: 11825551. DOI: 10.1007/s00432-025-06119-8.

References

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Cieply B, Zeng G, Proverbs-Singh T, Geller D, Monga S . Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2008; 49(3):821-31. PMC: 2657345. DOI: 10.1002/hep.22695. View

Xu L, Liu C, Gao G, Yu X, Zhang R, Wang J . Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma. World J Surg. 2010; 34(5):1039-45. DOI: 10.1007/s00268-010-0417-4. View

Kalathil S, Lugade A, Miller A, Iyer R, Thanavala Y . Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013; 73(8):2435-44. PMC: 3645275. DOI: 10.1158/0008-5472.CAN-12-3381. View

Song J, Ge Z, Yang X, Luo Q, Wang C, You H . Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. Cancer Lett. 2014; 356(2 Pt B):713-20. DOI: 10.1016/j.canlet.2014.10.021. View

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B . Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144(4):829-40. PMC: 3624083. DOI: 10.1053/j.gastro.2013.01.001. View

Seki E, De Minicis S, Osterreicher C, Kluwe J, Osawa Y, Brenner D . TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007; 13(11):1324-32. DOI: 10.1038/nm1663. View

Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K . Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol. 2006; 168(4):1155-68. PMC: 1606561. DOI: 10.2353/ajpath.2006.050204. View

Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei X . Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010; 101(8):1913-9. PMC: 11158749. DOI: 10.1111/j.1349-7006.2010.01614.x. View

10.

Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S . Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One. 2013; 8(1):e54499. PMC: 3547926. DOI: 10.1371/journal.pone.0054499. View

11.

Hirschfield G, Karlsen T, Lindor K, Adams D . Primary sclerosing cholangitis. Lancet. 2013; 382(9904):1587-99. DOI: 10.1016/S0140-6736(13)60096-3. View

12.

Zucman-Rossi J, Villanueva A, Nault J, Llovet J . Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology. 2015; 149(5):1226-1239.e4. DOI: 10.1053/j.gastro.2015.05.061. View

13.

Zhao S, Wang J, Qin C . Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res. 2014; 33:103. PMC: 4265318. DOI: 10.1186/s13046-014-0103-8. View

14.

Boulter L, Guest R, Kendall T, Wilson D, Wojtacha D, Robson A . WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest. 2015; 125(3):1269-85. PMC: 4362247. DOI: 10.1172/JCI76452. View

15.

Lau E, Lo J, Cheng B, Ma M, Lee J, Ng J . Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell Rep. 2016; 15(6):1175-89. DOI: 10.1016/j.celrep.2016.04.019. View

16.

Lai K, Shang S, Lohia N, Booth G, Masse D, Fausto N . Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet. 2011; 7(6):e1002147. PMC: 3121762. DOI: 10.1371/journal.pgen.1002147. View

17.

Haybaeck J, Zeller N, Wolf M, Weber A, Wagner U, Kurrer M . A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009; 16(4):295-308. PMC: 4422166. DOI: 10.1016/j.ccr.2009.08.021. View

18.

Cox D, Brennan M, Moran N . Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010; 9(10):804-20. DOI: 10.1038/nrd3266. View

19.

Ding B, Cao Z, Lis R, Nolan D, Guo P, Simons M . Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. 2013; 505(7481):97-102. PMC: 4142699. DOI: 10.1038/nature12681. View

20.

Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H . Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009; 16(9):2555-64. DOI: 10.1245/s10434-009-0568-4. View